因赛特制药

US · INCY #803 按市值排名上市于 1970

113.07 -0.20 -0.18%

实时 - 追踪5344个代码 - 心跳于263秒前 · 2026-10-16 19:54

✦ 量化股权信号计算方式说明

减持

最近一期（2026/Q3）披露持股的机构数量减少了2家。
机构持股总比例下降了0.7个百分点。

机构持股

机构持股比例: 102.57% -0.73pp
机构数量: 1,087 -2
数据截至: 2026/Q3 较上一报告期

持股变动 vs 资金流向

方向一致

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund69.67%

Hedge Fund23.98%

Government Pension Fund3.48%

Public Company2.59%

Private Company1.29%

Sovereign Wealth Fund0.67%

Individual/Insider0.47%

Family Office/Trust0.21%

VC/PE Fund0.21%

主要股东截至 2026-09-30

Baker Bros. Advisors LP 15.33% · 31.07M 股

BlackRock 8.90% · 18.03M 股

Vanguard Capital Management, LLC 5.90% · 11.97M 股

Dodge & Cox 5.90% · 11.96M 股

State Street Global Advisors 4.80% · 9.72M 股

Vanguard Portfolio Management, LLC 3.84% · 7.79M 股

AQR Capital Management 2.56% · 5.18M 股

Geode Capital Management, LLC 2.34% · 4.75M 股

LSV Asset Management 2.03% · 4.12M 股

Wellington Management Group 1.76% · 3.58M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 33次买入 · 17次卖出

姓名	职务	持股比例
Baker Bros. Advisors LP	--	15.33%
Julian Baker	Lead Independent Director	0.14%
Herve Hoppenot	Chairperson & CEO	0.04%
Paula Swain	Officer	0.03%
Christiana Stamoulis	Chief Financial Officer	0.03%
Paul Clancy	Independent Director	0.01%
Jean-Jacques Bienaime	Independent Director	0.01%
Edmund Harrigan	Independent Director	0.01%
Jacqualyn Fouse	Independent Director	0.01%
David Gardner	Chief Strategy Officer	0.01%

内部人交易最近的 Form 4 申报记录

日期	姓名	职务	类型	股数	价格
2026-09-30	Lee Heeson	Executive VP & Head of Incyte International	Sale to Issuer	-463	$117.14
2026-09-29	Edmund Harrigan	Independent Director	Other Acquisition	+206	$121.35
2026-09-29	Baker Bros. Advisors LP	--	Other Acquisition	+644	--
2026-09-29	Paul Clancy	Independent Director	Other Acquisition	+203	$121.35
2026-09-21	David Gardner	Chief Strategy Officer	Sale to Issuer	-920	$126.93
2026-09-14	Pablo Cagnoni	President and Head of Research & Development	Derivative Exercise and Sale	-23,218	$61.18–120.50
2026-08-24	Soni Basi	Executive Vice President	Sale to Issuer	-504	$129.72
2026-08-18	Pablo Cagnoni	President and Head of Research & Development	Open Market Disposition	-10,801	$125.56
2026-08-11	Pablo Cagnoni	President and Head of Research & Development	Open Market Disposition	-10,803	$120.04
2026-08-04	Pablo Cagnoni	President and Head of Research & Development	Open Market Disposition	-10,640	$122.69
2026-08-04	Patrick Mayes	Vice President of Biotherapeutic Research	Derivative Exercise and Sale	-2,207	$106.47–123.99
2026-08-02	Patrick Mayes	Vice President of Biotherapeutic Research	Derivative Exercise and Sale	-45,767	$61.18–122.19
2026-07-30	Pablo Cagnoni	President and Head of Research & Development	Open Market Disposition	-15,888	$119.70
2026-07-30	Patrick Mayes	Vice President of Biotherapeutic Research	Open Market Disposition	-2,187	$119.41
2026-07-22	Michael Morrissey	Executive VP & Head of Global Technical Operations	Other Derivative Acquisition	+6,426	$116.69
2026-07-22	Michael Morrissey	Executive VP & Head of Global Technical Operations	Other Derivative Acquisition	+8,999	--
2026-07-22	Lee Heeson	Executive VP & Head of Incyte International	Other Derivative Acquisition	+13,498	--
2026-07-22	Lee Heeson	Executive VP & Head of Incyte International	Other Derivative Acquisition	+15,423	$116.69
2026-07-15	Pablo Cagnoni	President and Head of Research & Development	Other Acquisition	+13,403	--
2026-07-15	Pablo Cagnoni	President and Head of Research & Development	Other Derivative Acquisition	+33,508	--

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 19:54:46 · 仅供参考，不构成投资建议，也未考虑您的具体情况。